Biblio

Author Title Type [ Year

]

Filters: Author is Chen, Jia [Clear All Filters]

2023

Chen J, Labopin M, Pabst T, Zhang X, Jiang E, Tucci A, Cornelissen J, Meijer E, Khevelidze I, Polge E, et al. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global co. Bone Marrow Transplant. 2023.

Han W, Qiu H-Y, Sun S, Fu Z-C, Wang G-Q, Qian X, Wang L, Zhai X, Wei J, Wang Y, et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Cell Stem Cell. 2023.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.

Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, Xu Y, Xu N, Luo Y, Deng L, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.

Zhang Z, Long Y, Yin X, Wang W, Li W, Chen T, Chen J, Chen X, Wang B, Ma J. Metabolome and Transcriptome Analysis of Sulfur-Induced Kiwifruit Stem Laccase Gene Involved in Syringyl Lignin Synthesis against Bacterial Canker. J Agric Food Chem. 2023.

Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.

Lai X, Xiao J, Wang T, Hou C, Chen J, Wu D, Xu Y. Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission. Leuk Lymphoma. 2023:1-9.

2022

Chu M, Hu S, Shen Y, Shen D, Zhan Y, Fan Y, Chen J, Tang X, Wu D, Xu Y. Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation. Bone Marrow Transplant. 2022.

Shen W-J, Still C, Han L, Yang P, Chen J, Wosczyna M, Rando TA, Salmon BJean Rene, Perez KC, Li J, et al. Corrigendum to "Hormone sensitive lipase ablation promotes bone regeneration" [Biochim. Biophys. Acta Mol. Basis Dis. Volume 1868, Issue 9, 1 September 2022, 166449]. Biochim Biophys Acta Mol Basis Dis. 2022;1868(11):166506.

Shen W-J, Still IIChris, Han L, Yang P, Chen J, Wosczyna M, Salmon BJean Rene, Perez KC, Li J, Cuevas PL, et al. Hormone sensitive lipase ablation promotes bone regeneration. Biochim Biophys Acta Mol Basis Dis. 2022:166449.

Zhu J, Chen J. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022.

Pan T, Qi J, Tang Y, Yao Y, Chen J, Wang H, Yang J, Xu X, Shi Q, Liu Y, et al. N-acetylcysteine as prophylactic therapy for transplant-associated thrombotic microangiopathy: a randomized, placebo-controlled trial. Transplant Cell Ther. 2022.

Cheng Q, Wang D, Lai X, Liu Y, Zuo Y, Zhang W, Lei L, Chen J, Liu H, Wang Y, et al. The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell-mediated graft-versus-host disease. Blood. 2022.

Yang L, Cheng J, Li F, Qian R, Zhang X, Jin S, He X, Xu T, Hu X, Ma X, et al. The predictive value of pulmonary function test before transplantation for chronic pulmonary graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation. BMC Pulm Med. 2022;22(1):473.

2019

Yang Y, Liu Y, Lu Q, Chen J, Luo H, Ma P. [Application of NGS-based SNP haplotyping for preimplantation genetic diagnosis for beta-thalassemia and HLA matching]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019;36(11):1090-1093.

Li C, Zhang Y, Zhang C, Chen J, Lou X, Chen X, Kang L, Xu N, Li M, Tan J, et al. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. JCI Insight. 2019;5.

Huang H, Zhang L, Jiang Y, Liu S, Jin Z, Chen J, Xiao X, Ruan J, Zhang X, Wu D. Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation. Ann Hematol. 2019.

Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, Deng L, Liang X, Huang F, Fan Z, et al. Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. Biol Blood Marrow Transplant. 2019.

2018

Ru Y, Chen J, Wu D. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. Eur J Haematol. 2018.

Liu S, Han J, Gong H, Li Y, Bao X, Qi J, Liu H, Chen J, Wu X, Xu Y, et al. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Sci Rep. 2018;8(1):10328.

2015

Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, et al. KIR2DS4 and its variant KIR1D are associated with aGVHD, CMV, and OS after sibling-related HLA matched transplantation for patients whose donors belong to the KIR gene haplotype A. Biol Blood Marrow Transplant. 2015.

Han Y, Tang Y, Chen J, Liang J, Ye C, Ruan C, Wu D. Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study. JAMA Oncol. 2015;1(2):249-252.